Castle Biosciences is a provider of molecular diagnostics to improve cancer management decisions. DecisionDx®-Melanoma leverages tumor biology for prognostic insight into metastatic risk in melanoma, providing information independent of AJCC staging factors and sentinel lymph node status. DecisionDx®-UM enables accurate staging of five-year metastatic risk in uveal melanoma and is standard of care in a majority of ocular oncology practices.